Insulin receptor. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Insulin icodec CHEMBL4594581 |
Insulin receptor agonist Agonist Protein |
ChEMBL only | 9 |
| Insulin Degludec CHEMBL2107869 |
Insulin receptor agonist Agonist Protein |
ChEMBL only | 6 |
| Insulin glargine CHEMBL1201497 |
Insulin receptor agonist Agonist Protein |
ChEMBL only | 4 |
| Insulin aspart CHEMBL1201496 |
Insulin receptor agonist Agonist Protein |
ChEMBL only | 3 |
| Human Insulin CHEMBL1201631 |
Insulin receptor agonist Agonist Protein |
✓ Both | 2 |
| Insulin Lispro CHEMBL1201538 |
Insulin receptor agonist Agonist Protein |
ChEMBL only | 2 |
| Linsitinib CHEMBL1091644 |
Insulin receptor inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Insulin Detemir CHEMBL2104391 |
Insulin receptor agonist Agonist Protein |
ChEMBL only | — |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Gestational diabetes | 5 | Phase 3 |
| Hypoglycemia | 4 | Phase 3 |
| Type 1 diabetes mellitus | 4 | Phase 3 |
| Hyperglycemia | 3 | Phase 3 |
| Chronic kidney disease | 3 | Phase 3 |
| Cystic fibrosis | 3 | Phase 3 |
| Burkitt lymphoma | 2 | Phase 3 |
| Acute lymphoblastic leukemia | 2 | Phase 3 |
| Cirrhosis of liver | 2 | Phase 3 |
| Cystic fibrosis-related diabetes | 2 | Phase 3 |
| Ischemic stroke | 2 | Phase 3 |
| Lymphoblastic lymphoma | 2 | Phase 3 |
| Prediabetes syndrome | 2 | Phase 3 |
| Type 2 diabetes mellitus | 2 | Phase 3 |
| Alzheimer disease | 2 | Phase 2 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
